Moreover, combined treatments with SFN and withaferin A promoted cell death in breast cancer cells through the inhibition of DNMT1, DNMT3a, and HDAC activities in MCF-7 cells (Royston et al., 2017). Here, DNMT3A is linked to breast cancer.